Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Fulgent Genetics Revenue Tops Estimates

TheMotleyFool 
0 0 28.02.25
Fulgent Genetics Revenue Tops Estimates
 

Laboratory services and therapeutic development specialist Fulgent Genetics (NASDAQ:FLGT) delivered a standout performance in the fourth quarter, topping analysts' consensus estimates. On Friday, Feb. 28, the company reported adjusted EPS of $0.04, outstripping expectations of a $0.12 per-share loss. Q4 revenue climbed to $76.2 million, exceeding estimates of $74 million, marking an impressive annual growth of 8.1%.

Despite a GAAP earnings loss, the overall quarter showcased strength driven by a 14% increase in core revenue from its laboratory services segment.

Source: Fulgent Genetics. Note: Analyst consensus estimates for the quarter provided by FactSet. (YOY = Year over year.

Continue reading


Source Fool.com

Electro Power Systems S.A. Stock

Show more
Like: 0
FLGT
Share

Comments

Not a member yet? Sign up for free!